Welcome to our dedicated page for Biomarin Pharmaceutical SEC filings (Ticker: BMRN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioMarin Pharmaceutical Inc. filings document the regulatory record of a Nasdaq-listed biotechnology company focused on rare genetic diseases. Recent 8-K reports disclose operating and financial results, material events, material agreements, capital-structure matters and clinical or regulatory updates tied to products and programs such as VOXZOGO, PALYNZIQ, GALAFOLD and POMBILITI + OPFOLDA.
The company’s proxy materials describe board composition, shareholder voting matters, executive compensation, equity awards and other governance disclosures. Filing records also cover common stock listing details, financing activities, acquisition-related disclosures and business updates affecting BioMarin’s commercial rare-disease portfolio and development pipeline.
BioMarin Pharmaceutical executive Cristin Hubbard reported a routine tax-related share disposition. On this Form 4, 2,318 shares of Common Stock were withheld at $50.20 per share to cover tax obligations, described as a tax-withholding disposition. After this non-market transaction, Hubbard directly holds 42,472 shares.
BioMarin Pharmaceutical EVP and Chief R&D Officer Gregory R. Friberg sold shares in an open-market transaction. On May 7, 2026, he sold 3,281 shares of common stock at $53.85 per share. After this sale, he directly owns 51,818 shares of BioMarin common stock.
BMRN submitted a Form 144 notice reporting proposed sales of Common Stock through Fidelity Brokerage Services LLC on 05/07/2026. The filing lists 3,281 shares with an indicated aggregate value of $176,682.18 and references NASDAQ. It also shows recent compensation vesting and ESPP purchase items and a past sale of 6,326 shares on 02/26/2026 with value $381,937.07.
BioMarin Pharmaceutical Inc. reported lower profitability for the quarter ended March 31, 2026 while preparing for a major acquisition. Total revenues were $766.2 million, up modestly from $745.1 million, driven by higher sales of VOXZOGO, NAGLAZYME, BRINEURA and other enzyme therapies, partly offset by declines in ALDURAZYME and ROCTAVIAN after its market withdrawal.
Cost of sales rose to $195.0 million, compressing gross margin to 74.5% from 79.7%, mainly due to a $31.0 million charge tied to an unsuccessful NAGLAZYME manufacturing campaign. Research and development expense increased to $178.8 million and selling, general and administrative expense to $258.3 million, reflecting pipeline expansion and Amicus pre-close costs. Net income declined to $105.5 million, or $0.54 per diluted share, from $185.7 million.
Cash, cash equivalents and restricted cash equivalents increased to $3.07 billion, helped by liquidating investments and issuing $850.0 million of 5.5% senior notes due 2034, partly held in escrow. After quarter-end, BioMarin closed the approximately $4.8 billion all-cash acquisition of Amicus, adding GALAFOLD, POMBILITI + OPFOLDA and Phase 3 asset DMX-200, funded with cash on hand and new $2.8 billion term loans plus a $600.0 million revolving credit facility, significantly increasing long-term debt obligations.
BioMarin Pharmaceutical Inc. reported first-quarter 2026 results and raised its full-year 2026 revenue outlook. Total revenues were $766 million, up 3% year-over-year, driven by Enzyme Therapies and more patients starting VOXZOGO. GAAP net income fell to $106 million, with Non-GAAP income at $149 million, reflecting higher selling, R&D and manufacturing costs, including a $31 million NAGLAZYME manufacturing charge.
The company increased 2026 total revenue guidance to $3.825–$3.925 billion, mainly from adding GALAFOLD and POMBILITI + OPFOLDA after completing the Amicus acquisition. Enzyme Therapies revenue guidance rose by $500 million, while Non-GAAP diluted EPS guidance edged to $4.85–$5.05. Operating cash flow was $221 million in the quarter, and the company secured about $3.7 billion of new non-convertible debt to fund the Amicus transaction.
Vanguard Capital Management reported beneficial ownership of 10,113,219 shares of BioMarin Pharmaceutical Inc. Common Stock as of 03/31/2026, representing 5.25% of the class. The filing shows sole dispositive power over 10,113,219 shares and sole voting power over 1,470,055 shares.
The filing is a Schedule 13G disclosure listing passive/beneficial ownership by an investment manager and affiliated business divisions. The signature block is dated 04/29/2026 and is signed by Ashley Grim, Head of Global Fund Administration.
BioMarin Pharmaceutical Inc. completed its previously announced acquisition of Amicus Therapeutics, buying all Amicus shares for $14.50 in cash per share, implying total equity value of about $4.8 billion. Amicus now operates as a wholly owned subsidiary.
To fund the cash deal, BioMarin entered into new senior secured credit facilities consisting of a $2.0 billion Term Loan B, a $800.0 million Term Loan A, and a $600.0 million revolving credit facility, alongside its previously issued 5.500% Senior Notes due 2034 and cash on hand. The term loans were fully drawn at closing, while the revolver remains available for working capital and general corporate purposes.
The new credit agreement is secured by a first‑priority lien on substantially all assets of BioMarin and certain subsidiaries and includes financial covenants, including a Total Net Leverage Ratio cap of 3.50 to 1.00 (temporarily 4.00 to 1.00 in some acquisition scenarios) and a minimum Interest Coverage Ratio of 3.00 to 1.00. With Amicus, BioMarin adds marketed rare‑disease therapies Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease, plus U.S. rights to late‑stage candidate DMX‑200 for focal segmental glomerulosclerosis.
BioMarin Pharmaceutical Inc. completed its previously announced acquisition of Amicus Therapeutics, buying all Amicus shares for $14.50 in cash per share, implying total equity value of about $4.8 billion. Amicus now operates as a wholly owned subsidiary.
To fund the cash deal, BioMarin entered into new senior secured credit facilities consisting of a $2.0 billion Term Loan B, a $800.0 million Term Loan A, and a $600.0 million revolving credit facility, alongside its previously issued 5.500% Senior Notes due 2034 and cash on hand. The term loans were fully drawn at closing, while the revolver remains available for working capital and general corporate purposes.
The new credit agreement is secured by a first‑priority lien on substantially all assets of BioMarin and certain subsidiaries and includes financial covenants, including a Total Net Leverage Ratio cap of 3.50 to 1.00 (temporarily 4.00 to 1.00 in some acquisition scenarios) and a minimum Interest Coverage Ratio of 3.00 to 1.00. With Amicus, BioMarin adds marketed rare‑disease therapies Galafold for Fabry disease and Pombiliti + Opfolda for Pompe disease, plus U.S. rights to late‑stage candidate DMX‑200 for focal segmental glomerulosclerosis.
BioMarin Pharmaceutical Inc. reports that France’s Ministry of Economics and Finance has granted foreign direct investment clearance for its planned merger with Amicus Therapeutics. This French FDI clearance satisfies the final outstanding regulatory condition under the Merger Agreement, aside from items to be completed at closing.
The merger, in which Amicus will become a wholly owned subsidiary of BioMarin, is expected to close on April 27, 2026. The companies caution that this timing and other expectations are forward-looking and subject to risks described in their SEC filings and the Amicus merger proxy.
BioMarin Pharmaceutical Inc. is asking stockholders to elect ten directors, ratify KPMG as auditor, approve executive pay on an advisory basis, and approve an amendment increasing shares reserved under the 2017 Equity Incentive Plan at its June 2, 2026 virtual annual meeting.
The proxy highlights 2025 revenue of $3.2 billion, up 13%, with VOXZOGO reaching $927 million. It describes an all-cash agreement to acquire Amicus Therapeutics for about $4.8 billion and the completed $270 million acquisition of Inozyme Pharma. The Board chair role will transition from Richard A. Meier to Ian T. Clark.